From those wonderful folks who brought you drug importation: “World Pricing”

  • by: |
  • 12/22/2006
Having a slow morning? Today at 10:30 a.m., U.S. Representative Rahm Emanuel (D-IL) will announce bipartisan legislation aimed at “driving down the price of prescription drugs.” The Pharmaceutical Market Access and Drug Safety Act will be cosponsored in the House of Representatives by U.S. Representative Jo Ann Emerson (R-MO) and in the United States Senate by Senators Byron Dorgan (D-ND) and Olympia Snowe (R-ME).

So, you’d expect that these fine legislators to have a solid track record against protectionism, right? Nope.

Senator Olympia Snowe (R-ME) fiercely protects against cheap imports from foreign countries when they negatively affects constituencies in her backyard. She supported the US Government’s findings that softwood lumber imports from Canada were subsidized and unfairly priced. “The implementation of the softwood lumber agreement this morning brings a successful resolution to a long and often difficult dispute,” Senator Snowe said. “This agreement levels the playing field for the softwood lumber industry and brings an end to the unfair subsidizing of the Canadian lumber industry that had threatened thousands of softwood lumber industry jobs in Maine.”

What about unfairly negotiated foreign prices for on-patent pharmaceuticals. Nope.

Senator Byron Dorgan (D-ND) is normally a staunch protectionist. Similar to Senator Snowe, Senator Dorgan staunchly defended the wheat farmers in North Dakota against subsidized imports of wheat from Canada. He went as far as to give Prairie Home Companion-worthy testimony about a family farmer at a recent Congressional hearing. He said, “The question for the "government," it seems to me that is posed by Kevin Neece and others is will someone finally stand up for family producers, for family farmers in this country and insist and demand unfair trade and insist and demand that our trading partners, in this instance Canada, comply with fair trade rules and comply with the agreements that were reached.”

What about unfairly negotiated foreign prices for on-patent pharmaceuticals that unfairly place the financial burden of R&D on the American health care consumer? Nada.

And the leader of the pack, Rahm Emanuel (D-IL), supported the Byrd Amendment. When the Deficit Reduction Act of 2005 was passed, he co-wrote a dissenting opinion that stated: “Ensuring fair trade enables U.S. manufacturers and their workers to make continued investments to preserve their global competitiveness.”

What about unfair European trade practices that threaten pharmaceutical companies with patent expropriation if they don’t accept absurdly low “reference prices” for new and innovative products? Zilch.

But who needs consistency when you’ve got sound bites?
CMPI

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog